Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.

Ma CC, Liu ZP.

Anticancer Agents Med Chem. 2017;17(3):395-403. doi: 10.2174/1871520616666160223120207.

PMID:
26902599
2.

Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.

Fan YH, Ding HW, Liu DD, Song HR, Xu YN, Wang J.

Bioorg Med Chem. 2018 May 1;26(8):1675-1685. doi: 10.1016/j.bmc.2018.02.015. Epub 2018 Feb 13.

PMID:
29475582
3.

Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.

Lu L, Sha S, Wang K, Zhang YH, Liu YD, Ju GD, Wang B, Zhu HL.

Chem Pharm Bull (Tokyo). 2016 Nov 1;64(11):1576-1581. Epub 2016 Sep 1.

4.

Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents.

Amin KM, Eissa AA, Abou-Seri SM, Awadallah FM, Hassan GS.

Eur J Med Chem. 2013 Feb;60:187-98. doi: 10.1016/j.ejmech.2012.12.004. Epub 2012 Dec 12.

PMID:
23291120
5.

Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.

Fan YH, Li W, Liu DD, Bai MX, Song HR, Xu YN, Lee S, Zhou ZP, Wang J, Ding HW.

Eur J Med Chem. 2017 Oct 20;139:95-106. doi: 10.1016/j.ejmech.2017.07.074. Epub 2017 Aug 1.

PMID:
28800461
6.

Design, Synthesis, and In Vitro Evaluation of Novel 3, 7-Disubstituted Coumarin Derivatives as Potent Anticancer Agents.

Wang Y, Liu H, Lu P, Mao R, Xue X, Fan C, She J.

Chem Biol Drug Des. 2015 Oct;86(4):637-47. doi: 10.1111/cbdd.12531. Epub 2015 Mar 1.

PMID:
25626768
7.

Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.

Ding HW, Deng CL, Li DD, Liu DD, Chai SM, Wang W, Zhang Y, Chen K, Li X, Wang J, Song SJ, Song HR.

Eur J Med Chem. 2018 Feb 25;146:460-470. doi: 10.1016/j.ejmech.2018.01.081. Epub 2018 Jan 31.

PMID:
29407971
8.

Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR signaling.

Liu H, Wang Y, Sharma A, Mao R, Jiang N, Dun B, She JX.

Anticancer Drugs. 2015 Jul;26(6):667-77. doi: 10.1097/CAD.0000000000000232.

PMID:
25811964
9.

Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.

Peng W, Tu ZC, Long ZJ, Liu Q, Lu G.

Eur J Med Chem. 2016 Jan 27;108:644-654. doi: 10.1016/j.ejmech.2015.11.038. Epub 2015 Dec 2.

PMID:
26731167
10.

Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.

Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, Zhao Y, Zhang H, Qi C.

Eur J Med Chem. 2017 Sep 29;138:669-688. doi: 10.1016/j.ejmech.2017.07.005. Epub 2017 Jul 4.

PMID:
28711702
11.

Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.

Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z, Mao X.

J Hematol Oncol. 2014 Jan 15;7:9. doi: 10.1186/1756-8722-7-9.

12.

Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.

Thakur A, Singla R, Jaitak V.

Eur J Med Chem. 2015 Aug 28;101:476-95. doi: 10.1016/j.ejmech.2015.07.010. Epub 2015 Jul 10. Review.

PMID:
26188907
13.

Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents.

Zhang W, Li Z, Zhou M, Wu F, Hou X, Luo H, Liu H, Han X, Yan G, Ding Z, Li R.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):799-807. doi: 10.1016/j.bmcl.2013.12.095. Epub 2013 Dec 29.

PMID:
24418772
14.

Design, synthesis, and anticancer properties of novel benzophenone-conjugated coumarin analogs.

Lakshmi Ranganatha V, Zameer F, Meghashri S, Rekha ND, Girish V, Gurupadaswamy HD, Khanum SA.

Arch Pharm (Weinheim). 2013 Dec;346(12):901-11. doi: 10.1002/ardp.201300298. Epub 2013 Oct 29.

PMID:
24170414
15.

Design and synthesis of new coumarin hybrids and insight into their mode of antiproliferative action.

Elshemy HAH, Zaki MA.

Bioorg Med Chem. 2017 Feb 1;25(3):1066-1075. doi: 10.1016/j.bmc.2016.12.019. Epub 2016 Dec 19.

PMID:
28038941
16.

Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.

Dong FD, Liu DD, Deng CL, Qin XC, Chen K, Wang J, Song HR, Ding HW.

Bioorg Med Chem. 2018 Aug 7;26(14):3982-3991. doi: 10.1016/j.bmc.2018.06.022. Epub 2018 Jun 18.

PMID:
29937355
17.

Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids.

Kraljević TG, Harej A, Sedić M, Pavelić SK, Stepanić V, Drenjančević D, Talapko J, Raić-Malić S.

Eur J Med Chem. 2016 Nov 29;124:794-808. doi: 10.1016/j.ejmech.2016.08.062. Epub 2016 Aug 31.

PMID:
27639370
18.

Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.

Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Mar 12;9:1555-84. doi: 10.2147/DDDT.S74197. eCollection 2015.

19.

Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.

Zhang JQ, Luo YJ, Xiong YS, Yu Y, Tu ZC, Long ZJ, Lai XJ, Chen HX, Luo Y, Weng J, Lu G.

J Med Chem. 2016 Aug 11;59(15):7268-74. doi: 10.1021/acs.jmedchem.6b00235. Epub 2016 Aug 2.

PMID:
27427973
20.

Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.

Zhang N, Yu Z, Yang X, Zhou Y, Wang J, Zhang SL, Wang MW, He Y.

Eur J Med Chem. 2018 Oct 5;158:707-719. doi: 10.1016/j.ejmech.2018.09.002. Epub 2018 Sep 6.

PMID:
30245395

Supplemental Content

Support Center